A clinical trial has shown that the immunotherapy drug pembrolizumab increased survival rates for head and neck cancer patients with intermediate risk.
Immunotherapy drug bolsters head and neck cancer treatment
- ScienceDaily
- 28. 2 2022 (23:08)
A clinical trial has shown that the immunotherapy drug pembrolizumab increased survival rates for head and neck cancer patients with intermediate risk.